Serum miR-499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer

Li,Ming; Zhang,Qian; Wu,Liang; Jia,Chengyou; Shi,Fuhua; Li,Shaocai; Peng,Aimei; Zhang,Guoliang; Song,Xiaolian; Wang,Changhui

doi:10.3892/or.2014.3029

Serum miR-499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer

Authors:
- Ming Li
- Qian Zhang
- Liang Wu
- Chengyou Jia
- Fuhua Shi
- Shaocai Li
- Aimei Peng
- Guoliang Zhang
- Xiaolian Song
- Changhui Wang
View Affiliations

Affiliations: Department of Respiratory Medicine, Shanghai 10th People's Hospital, Tongji University, Shanghai 200072, P.R. China, Department of Nephrology, Huashan Hospital, Fudan University, Shanghai 200032, P.R. China, Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, P.R. China, Department of Nuclear Medicine, Shanghai 10th People's Hospital, Tongji University, Shanghai 200072, P.R. China, Department of Neural Medicine, People's Hospital of Zunhua County, Tangshan, Hebei 064200, P.R. China, Department of Cardiology, People's Hospital of Zunhua County, Tangshan, Hebei 064200, P.R. China
Published online on: February 18, 2014 https://doi.org/10.3892/or.2014.3029
Pages: 1961-1967

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to determine whether serum miR-499 may be used as a biomarker for early detection of non-small cell lung cancer (NSCLC). The present study was designed as an initial screening phase and a subsequent validation phase. In the screening phase, we analyzed serum levels of miR-499 in a subset of 40 patients with stage I (n=20) and stage IV (n=20) NSCLC. In the validation phase, miR-499 expression levels in serum (n=514) and tissue (n=136) from NSCLC patients were detected in a large and independent cohort of 514 patients. miR-499 in the screening phase was found to be significantly elevated in the serum of stage I NSCLC patients compared with that in stage IV NSCLC patients (P<0.001). Validation analysis showed that serum miR-499 levels were robust in differentiating NSCLC patients from control subjects [area under the curve (AUC)=0.906; 95% confidence interval (CI)=0.879 to 0.929). Serum miR-499 levels were significantly lower in stage III and IV patients compared with those with stage I (both P<0.001) or II (both P<0.001). Low serum miR-499 levels were associated with shorter overall survival and served as an independent prognostic biomarker in NSCLC patients [hazard ratio (HR)=1.63; 95% CI=1.33-2.0; P<0.0001). In addition, low serum levels of miR-499 indicated a poor disease-free survival in stage I-II NSCLC patients. Serum miR-499 may prove to be a promising biomarker for early detection and prognosis prediction of NSCLC.

View Figures

View References

1	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
2	Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol. 2:533–543. 2001.PubMed/NCBI
3	Li M, Zhang Q, Fu P, et al: Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. PLoS One. 7:e372292012. View Article : Google Scholar : PubMed/NCBI
4	Smith RA, Brooks D, Cokkinides V, et al: Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin. 63:88–105. 2013. View Article : Google Scholar
5	Goldstraw P, Ball D, Jett JR, et al: Non-small-cell lung cancer. Lancet. 378:1727–1740. 2011. View Article : Google Scholar : PubMed/NCBI
6	Rami-Porta R and Goldstraw P: Strength and weakness of the new TNM classification for lung cancer. Eur Respir J. 36:237–239. 2010. View Article : Google Scholar : PubMed/NCBI
7	Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 9:102–114. 2008. View Article : Google Scholar : PubMed/NCBI
8	van Kouwenhove M, Kedde M and Agami R: MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer. 11:644–656. 2011.PubMed/NCBI
9	Chen X, Ba Y, Ma L, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
10	Kong YW, Ferland-McCollough D, Jackson TJ and Bushell M: microRNAs in cancer management. Lancet Oncol. 13:e249–e258. 2012. View Article : Google Scholar : PubMed/NCBI
11	Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
12	Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
13	Voortman J, Goto A, Mendiboure J, et al: MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res. 70:8288–8298. 2010. View Article : Google Scholar : PubMed/NCBI
14	Hu Z, Chen X, Zhao Y, et al: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 28:1721–1726. 2010. View Article : Google Scholar : PubMed/NCBI
15	Markou A, Sourvinou I, Vorkas PA, et al: Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer. 81:388–396. 2013. View Article : Google Scholar : PubMed/NCBI
16	Vinci S, Gelmini S, Pratesi N, et al: Genetic variants in miR-146a, miR-149, miR-196a2, miR-499 and their influence on relative expression in lung cancers. Clin Chem Lab Med. 49:2073–2080. 2011.
17	Kroh EM, Parkin RK, Mitchell PS and Tewari M: Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 50:298–301. 2010. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔ^C^T method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Peltier HJ and Latham GJ: Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA. 14:844–852. 2008. View Article : Google Scholar : PubMed/NCBI
20	Ruopp MD, Perkins NJ, Whitcomb BW and Schisterman EF: Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom J. 50:419–430. 2008. View Article : Google Scholar : PubMed/NCBI
21	Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
22	Yu SL, Chen HY, Chang GC, et al: MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 13:48–57. 2008. View Article : Google Scholar : PubMed/NCBI
23	Takamizawa J, Konishi H, Yanagisawa K, et al: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 64:3753–3756. 2004.PubMed/NCBI
24	Lawrie CH, Gal S, Dunlop HM, et al: Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 141:672–675. 2008. View Article : Google Scholar : PubMed/NCBI
25	Boeri M, Verri C, Conte D, et al: MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA. 108:3713–3718. 2011. View Article : Google Scholar : PubMed/NCBI
26	Wang GK, Zhu JQ, Zhang JT, et al: Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 31:659–666. 2010. View Article : Google Scholar : PubMed/NCBI
27	Donaldson A, Natanek SA, Lewis A, et al: Increased skeletal muscle-specific microRNA in the blood of patients with COPD. Thorax. 68:1140–1149. 2013. View Article : Google Scholar : PubMed/NCBI
28	National Lung Screening Trial Research Team. Aberle DR, Adams AM, Berg CD, et al: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 365:395–409. 2011. View Article : Google Scholar : PubMed/NCBI
29	Infante M, Cavuto S, Lutman FR, et al: A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med. 180:445–453. 2009.PubMed/NCBI
30	Shen J, Liu Z, Todd NW, et al: Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer. 11:3742011. View Article : Google Scholar : PubMed/NCBI
31	Cazzoli R, Buttitta F, Di Nicola M, et al: microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol. 8:1156–1162. 2013. View Article : Google Scholar : PubMed/NCBI